Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF
Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF Summary
Accession # Q6PE46
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
BCMA, B cell maturation antigen, is a member of the TNF receptor superfamily. It has been designated TNFRSF17. BCMA is a type III membrane protein containing one extracellular cysteine rich domain. Within the TNFRSF, it shares the highest homology with TACI. BCMA and TACI have both been shown to bind to APRIL and BAFF, members of the TNF ligand superfamily. BCMA expression has been found in immune organs and mature B cell lines. Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment. The binding of BCMA to APRIL or BAFF has been shown to stimulate IgM production in peripheral blood B cells and increase the survival of cultured B cells. This data suggests that BCMA may play an important role in B cell development, function and regulation. Human BCMA is a 184 amino acid (aa) protein consisting of a 54 aa extracellular domain, a 23 aa transmembrane domain, and a 107 aa intracellular domain. Mouse and human BCMA share 62% amino acid identity.
- Madry, C. et al. (1998) Int. Immunol. 10:1693.
- Gras, M. et al. (1995) Int. Immunol. 7:1093.
- Kwon, B. et al. (1999) Curr. Opin. Immunol. 11:340.
- Marsters, S. et al. (2000) Curr. Biol. 10:785.
- Thompson, J. et al. (2000) J. Exp. Med. 192:129.
Citations for Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
Authors: DX Bu, R Singh, EE Choi, M Ruella, S Nunez-Cruz, KG Mansfield, P Bennett, N Barton, Q Wu, J Zhang, Y Wang, L Wei, S Cogan, T Ezell, S Joshi, KJ Latimer, B Granda, WR Tschantz, RM Young, HA Huet, CJ Richardson, MC Milone
Sample Types: Protein
Applications: CAR-T (SPR)
Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.
Authors: Isik G, Sliepen K, van Montfort T, Sanders R
PLoS ONE, 2014;9(9):e107683.
Sample Types: Protein
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF
Average Rating: 5 (Based on 2 Reviews)
Have you used Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Reason for Rating: 97% monomer